Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?

Assiut University

Status: Unknown

Conditions: COVID-19; BCG Vaccination

Treatments: Diagnostic Test: Tuberculin test

Study type: Observational

Funder types: Other

Identifiers

NCT04347876

AssiutU12

Details and patient eligibility

About

There is no evidence that the Bacille Calmette-Guérin vaccine (BCG) protects people against infection with COVID-19 virus. Two clinical trials addressing this question are underway, and WHO will evaluate the evidence when it is available. In the absence of evidence, WHO does not recommend BCG vaccination for the prevention of COVID-19. WHO continues to recommend neonatal BCG vaccination in countries or settings with a high incidence of tuberculosis. There is experimental evidence from both animal and human studies that the BCG vaccine has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown

Enrollment: 100 estimated patients

Sex: All

Ages: 12 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• COVID-19 positive cases admitted to hospitals in Upper Egypt

Exclusion criteria

• None

Trial design

100 participants in 2 patient groups

Group A

Description:

COVID-19 positive with positive tuberculin test

Treatment:

Diagnostic Test: Tuberculin test

Group B

Description:

COVID-19 positive with negative tuberculin test

Treatment:

Diagnostic Test: Tuberculin test